Cytonics' preclinical results indicate signs of safety & efficacy
Cytonics is excited to announce its recent preclinical research results: “The purpose of this pilot preclinical study was to examine whether CYT-108 is a feasible drug candidate for treating osteoarthritis,” comments Cytonics President Joey Bose. Read more here.
“The results demonstrated CYT-108, our lead drug candidate, was generally tolerated when injected. Moreover, we also observed slight cartilage-protective effects when CYT-108 was administered into damaged joints.”